Brief: Biostage files for FDA orphan drug designation for cellspan esophageal implant
29/06/2016 13:23
June 29 (Reuters) - Biostage Inc BSTG.O
* Biostage files for FDA orphan drug designation for
cellspan esophageal implant
Source text for Eikon: ID:nPnBnlX7a
Further company coverage: BSTG.O
(Bengaluru Newsroom: +1 646 223 8780)
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer